Wave Life Sciences Aligns With FDA on Single Registrational Trial for WVE-006 in AATD
Wave plans a single two-year trial for WVE-006 in AATD after FDA feedback, with a one-year review for possible accelerated approval.
/ 490 items
#XY Event-Driven Stocks↓
McKesson and Cardinal Health Extend CVS Drug Supply Deals Through 2032
BofA kept Buy ratings, calling the news a clearing event.
Foghorn Therapeutics and Eli Lilly End SMARCA2 Cancer Program After Weak Phase 1 Results, Cut 40% of Staff
Foghorn and Lilly will not advance FHD-909 or their SMARCA2 degrader. Foghorn is cutting about 40% of staff to fund its pipeline into late 2029.
Wainwright Initiates Monte Rosa With a Buy as MRT-8102 Phase 1 Data Arrive
Wainwright cites a $565M enterprise value, cash into 2029, and multiple trials.
United Therapeutics Wins Patent Case Against Liquidia’s Yutrepia
A Delaware judge found Liquidia’s Yutrepia infringes United Therapeutics’ PH-ILD patent. Final judgment is next.
HETLIOZ Meets Phase III Endpoint in Delayed Sleep-Wake Phase Disorder; Vanda Plans FDA Filing
If approved, it would be the first FDA-approved medicine for the circadian disorder.